|Day Low/High||0.03 / 0.04|
|52 Wk Low/High||0.03 / 0.77|
Company Requests Scientific Advice Meeting with the MHRA (UK) to Discuss Next Steps
Patent covers a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union
With a promising treatment for solid tumor cancers coming down its pipeline, Propanc has its sights set on changing the way cancer is treated.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.